Hyeong In Ha
Overview
Explore the profile of Hyeong In Ha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
154
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim J, Kim S, Kim E, Ha H, Lee D, Lee Y, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075604
Background: The location of BRCA mutations within functional domains may affect sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapy. This study aimed to evaluate the progression-free survival (PFS)...
2.
Ha H, Yoon H, Song C, Kim E, Suh D, Kim K, et al.
Curr Oncol
. 2024 Nov;
31(11):6711-6722.
PMID: 39590126
Purpose: In this study, we aimed to retrospectively investigate the real-world clinical efficacy and adverse events of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in real-world clinical practice among patients with...
3.
Jeong Y, Kim D, Kim J, Kim S, Ha H, Park S, et al.
Cancer Res Treat
. 2024 Nov;
PMID: 39512063
Purpose: Nausea and vomiting are major non-hematological adverse events associated with niraparib maintenance therapy. This study aimed to investigate the time-trend patterns of niraparib-induced nausea and vomiting (NINV) and the...
4.
Kim J, Kim S, Park E, Ha H, Kim J, Coleman R, et al.
Gynecol Oncol
. 2024 Nov;
179:24-32.
PMID: 39491079
Background: Current treatment strategies for primary epithelial ovarian cancer (EOC) have significantly evolved, and the value of complete cytoreduction has not yet been reassessed. The study aimed to investigate the...
5.
Lee S, Kim J, Ha H, Lim M, Cho H
JCO Clin Cancer Inform
. 2024 Mar;
8:e2300150.
PMID: 38442323
Purpose: As the onset of cancer recurrence is not explicitly recorded in the electronic health record (EHR), a high volume of manual chart review is required to detect the cancer...
6.
Shim S, Lim J, Kim J, Lee Y, Ha H, Lim M, et al.
J Gynecol Oncol
. 2023 Dec;
35(3):e32.
PMID: 38130136
Objective: To evaluate trends in the incidence and survival outcomes of endometrial cancer (EC) based on the year of diagnosis, stage, age, and histologic types. Methods: Women with primary EC...
7.
Ha H, Kim J, Lim J, Song Y, Won Y, Lim M
J Gynecol Oncol
. 2023 Dec;
35(1):e31.
PMID: 38072401
Objective: To investigate the incidence and survival outcomes of ovarian carcinosarcoma in Korea between 1999 and 2018. Methods: Patients diagnosed with ovarian carcinosarcoma between 1999 and 2018 were identified from...
8.
Lee E, Lim J, Ha H, Lim M, Chang Y, Won Y, et al.
Front Oncol
. 2023 Oct;
13:1208320.
PMID: 37781206
Background: Second primary cancer has become an important issue among cancer survivors. This study sought to determine the differences in clinicopathologic outcomes between second primary breast cancer (SPBC) after ovarian...
9.
Suh D, Ha H, Lee Y, Lim J, Won Y, Lim M
J Gynecol Oncol
. 2023 Feb;
34(2):e39.
PMID: 36731896
Objective: To describe the incidence and survival outcomes of uterine cervical cancer during 1999-2018. Methods: Patients who were diagnosed with cervical cancer during 1999-2018 were identified in the Korea Central...
10.
Kim J, Lee D, Ha H, Jung J, Kim S, Lee H, et al.
BMC Cancer
. 2022 Nov;
22(1):1163.
PMID: 36357914
Background: Ureteral reconstruction is required after surgical resection of the tumor invading the urinary tract in ovarian cancer with low incidence. There are no currently reported surgical outcomes of ureteral...